The laboratory of Chris Peters, MD, is focused on addressing chronic pain after surgery. Chronic pain after surgery (CPAS) is now recognized as a major public health concern that can affect between 10 and 50 percent of patients depending on the type of surgery. Currently, there is no standard of medical care provided perioperatively to prevent CPAS. This is due in part to an incomplete knowledge of the risk factors and biological mechanisms that are responsible for postoperative pain transitioning from an acute stage that resolves with wound healing to a more chronic pain state. Various surgical, biological, inter-individual and psychosocial factors are associated with a greater incidence of CPAS.

Research Project Highlights

The ultimate goal of our research is to identify Food and Drug Administration (FDA)-approved and novel therapeutic approaches for preventing CPAS to introduce into clinical studies.

Our current projects include:

  • Modeling observations in rodents that patients with diminished preoperative endogenous pain inhibition are at greater risk for developing CPAS.
  • How disrupting spinal noradrenergic signaling influences spinal neural and glial plasticity promoting the transition from acute to a more persistent postoperative pain state.
  • Monitoring postoperative pain-related behaviors over time using mixed effects growth curve modeling, allowing us to examine the ability of socio-environmental conditions or pharmacological interventions to impair or improve several aspects of postoperative pain trajectory.

Recent clinical studies report that patients with diminished preoperative endogenous pain inhibition are at greater risk for developing CPAS. We modeled this observation in rodents by disrupted spinally projecting noradrenergic neurons prior to surgery using a targeted toxin (dopamine β hydroxylase conjugated to saporin). This manipulation results in prolonged mechanical hypersensitivity (Figure 1) and increased spinal glial activation in rats after plantar incision (Brennan incision model).

Figure 1

Figure 1: Disruption of spinal noradrenergic fibers prior to surgery using a targeted toxin (DβH-saporin) increased the duration of mechanical hypersensitivity following plantar incision in the rat. Longitudinal behavioral data is expresses as group averaged values (line and symbol) and modeled for treatment groups and individual rats using growth curve analysis (dashed lines with 95% CI) to examine changes over time of postoperative pain trajectory.

How disrupting spinal noradrenergic signaling influences spinal neural and glial plasticity promotes the transition from acute to a more persistent postoperative pain state.

Under NIH grant GM99863, we are studying how disrupting spinal noradrenergic signaling influences spinal neural and glial plasticity (Figure 2), promoting the transition from acute to a more persistent postoperative pain state. We use a combination of in vivo biochemical, pharmacological, behavioral and immunohistochemical methods as well as in vitro primary microglial and astrocyte cultures as part of these studies.

Figure 2

Figure 2: Potential mechanisms by which reduced spinal noradrenergic signaling contributes to the transition from acute to chronic postoperative pain.

Monitoring postoperative pain-related behaviors using mixed effects growth curve modeling

Research in the Pain Mechanisms lab is also focused on monitoring postoperative pain-related behaviors over time using mixed effects growth curve modeling. This type of analysis gives rise to intercept (initial pain at time 0), slope (linear rate of change in pain measure), and quadratic term (acceleration and deceleration over time reflecting inflections in change during recovery) parameters. The intercept, slope and quadratic term estimates can vary across individual rats (random effects) and as a function of treatment group or condition (fixed effects) allowing us to examine the ability of socio-environmental conditions or pharmacological interventions to impair or improve several aspects of postoperative pain trajectory.

The ultimate goal of this research is to identify Food and Drug Administration (FDA)-approved and novel therapeutic approaches for preventing CPAS to introduce into clinical studies.

Select Publications

Kiguchi N, Ding H, Peters CM, Kock ND, Kishioka S, Cline JM, Wagner JD, Ko MC. Altered expression of glial markers, chemokines, and opioid receptors in the spinal cord of type 2 diabetic monkeys. Biochim Biophys Acta. 2017 Jan; 1863(1):274-283. PMID: 27751964.

Tsuzuki S, Park SH, Eber MR, Peters CM, Shiozawa Y. Skeletal complications in cancer patients with bone metastases. Int J Urol. 2016 Oct; 23(10):825-832. PMID: 27488133.

Peters CM. Silencing Transient Receptor Potential Vanilloid Receptor Subtype I-containing Sensory Neurons to Treat Bone Cancer Pain. Anesthesiology. 2016 Jul; 125(1):17-9. PMID: 27176213.